A welcome move by Glenmark_Price cuts for Anti-cancer drugs

In a welcome move by India's leading pharmaceutical drug producer Glenmark Pharmaceuticals, the company has reduced the price for Erleva (erlotinib), Geftib (gefitinib) and Pexotra (pemetrexed) by about 55-70%. These drugs are used for the treatment of lung cancer.

 

DNA reports here, http://www.dnaindia.com/money/report-glenmark-cuts-lung-cancer-drug-price-2089524

 

The new prices of cancer drugs are as follows:

• Erleva (150 mg, 30 tablets) is Rs 9,700 (drop of 67.66% ),
• Geftib tablets 250 mg (1 box of 3 strips of 10 tablets each) is Rs 3,999 (drop of 63.63% );
• Pexotra injection 100 mg (1 vial) is Rs 2,000 (fall of 56% ) and
• Pexotra injection 500 mg (1 vial) is Rs 8,000 (fall of 60.87%).

 

Sujesh Vasudevan, executive VP, Glenmark, told DNA that more price reductions in different segments of the company's cancer drug portfolio are on the cards.